Circular cycle

Unlock a More Complete View of Cancer

Guardant Infinity™ is a robust nondestructive DNA methylation technology ushering in a new era for precision oncology.1

Characterize Cancer With Liquid Molecular Profiling Powered by Guardant Infinity™

Guardant Infinity offers unrivaled discovery power with combined genomic and epigenomic profiling for multidimensional insights from a single blood sample.

Minimally invasive—
requires only 2 tubes of blood

Guardant Infinity Liquid Core Module

Ensure that your drug development program stays ahead of the curve with all current and emerging biomarkers.

FEATURES & SPECIFICATIONS DETAILS 2,3
Extensive biomarker coverage
  • 753 genes, single nucleotide variants/insertions and deletions (SNV/Indels)
  • 405 copy number amplifications (CNAs)
  • 30 fusions
  • 45 copy number losses (CNLs)
  • Blood tumor mutation burden (bTMB) and microsatellite instability (MSI)
Methylation-based quantification of tumor fraction
  • 15 Mb methylation panel
Limited sample requirement
  • 15 Mb methylation panel
  • ≥2 mL of plasma (retrospective)
  • 2 x 10 mL of blood (prospective)
IO module
  • 203 genes
DNA damage and HRD module
  • 196 genes
Viral module
  • 15 genes

Guardant Infinity Provides Flexible Configurations to Unlock Essential Insights

Characterize Cancer With Tissue Molecular Profiling

Guardant Infinity offers multiomic tissue insights from an expanded genotyping profile of clinically relevant genes and new applications powered by epigenomics. See our core tissue module below.

Guardant Infinity Tissue Core Module

FEATURES & SPECIFICATIONS DETAILS 2,4-6
Expanded genotyping
  • 741 single nucleotide variants/insertions and deletions (SNV/Indels)
  • 34 copy number variations (CNVs)
  • 28 fusions/rearrangements
  • Tumor mutation burden (TMB) and microsatellite instability (MSI)
  • 47 promoter methylation regions
RNA-based fusion detection and PD-L1
  • 367 fusions7
  • 3 splice isoforms (MET, AR, EGFR)7
  • Programmed death-ligand 1 (PD-L1)7
Low sample requirement
  • 6 slides for next-generation sequencing (NGS) testing
  • Significantly less surface area than industry standard

Maximize Insights From Precious Tissue Samples

Tissue availability has always been a challenge in tissue-based comprehensive genomic profiling (CGP) testing. In a real-world CGP tissue availability assessment, more than 50% of samples did not meet the minimum surface area requirement of 25 mm2.2,6

Guardant Infinity requires less tumor tissue to efficiently analyze precious tissue samples.

Tissue on Guardant Infinity successfully processes 99% of challenging sample types, including fine needle aspirates and core needle biopsies.5

With genomic, epigenomic, and RNA-fusion data, Tissue on Guardant Infinity delivers breakthrough multiomic insights for every tissue sample.4,5

Get in Touch With Us To Learn About Our Additional Modules

  1. Guardant Health data on file. April 2024. Guardant Health, Inc. Redwood City, CA.
  2. Guardant Infinity™ Assay Specifications. February 2025. Guardant Health, Inc. Redwood City, CA.
  3. Guardant Health data on file. April 19, 2024. Guardant Health, Inc. Redwood City, CA.
  4. Guardant360® Tissue Assay Specifications. March 12, 2025. Guardant Health, Inc. Redwood City, CA.
  5. Guardant Health data on file. January 2025. Guardant Health, Inc. Redwood City, CA.
  6. Tomlins SA, Hovelson DH, Suga JM, et al. Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples. JCO Precis Oncol. 2021;5:1312-1324. doi:10.1200/PO.20.00472
  7. Opt-out ordering.